Welcome to LookChem.com Sign In|Join Free

CAS

  • or

624747-15-5

Post Buying Request

624747-15-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

624747-15-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 624747-15-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,4,7,4 and 7 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 624747-15:
(8*6)+(7*2)+(6*4)+(5*7)+(4*4)+(3*7)+(2*1)+(1*5)=165
165 % 10 = 5
So 624747-15-5 is a valid CAS Registry Number.

624747-15-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[[4-(2-tert-butylanilino)-2-methyl-3,4-dioxobutanoyl]oxyamino]-5-oxo-6-(2,3,5,6-tetrafluorophenoxy)hexanoic acid

1.2 Other means of identification

Product number -
Other names IDN 6556

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:624747-15-5 SDS

624747-15-5Downstream Products

624747-15-5Relevant articles and documents

A the graciousness favorable card lives synthetic method

-

, (2017/08/03)

A synthetic method for emricasan belongs to the technical field of drug chemical synthesis. The synthetic method comprises the steps: firstly carrying out acyl chlorination reaction on pyruvic acid and an acyl chlorination reagent to obtain pyruvoyl chlor

TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE

-

, (2016/08/17)

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions

First-in-class pan caspase inhibitor developed for the treatment of liver disease

Linton, Steven D.,Aja, Teresa,Armstrong, Robert A.,Bai, Xu,Chen, Long-Shiuh,Chen, Ning,Ching, Brett,Contreras, Patricia,Diaz, Jose-Luis,Fisher, Craig D.,Fritz, Lawrence C.,Gladstone, Patricia,Groessl, Todd,Gu, Xin,Herrmann, Julia,Hirakawa, Brad P.,Hoglen, Niel C.,Jahangiri, Kathy G.,Kalish, Vincent J.,Karanewsky, Donald S.,Kodandapani, Lalitha,Krebs, Joseph,McQuiston, Jeff,Meduna, Steven P.,Nalley, Kip,Robinson, Edward D.,Sayers, Robert O.,Sebring, Kristen,Spada, Alfred P.,Ternansky, Robert J.,Tomaselli, Kevin J.,Ullman, Brett R.,Valentino, Karen L.,Weeks, Suzanne,Winn, David,Wu, Joe C.,Yeo, Pauline,Zhang, Cheng-Zhi

, p. 6779 - 6782 (2007/10/03)

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 624747-15-5